Skip to main content
. 2022 Oct 24;10:1034373. doi: 10.3389/fped.2022.1034373

Figure 1.

Figure 1

Clinical course of patients treated with blinatumomab (blina). Blue Shading, Time From diagnosis; Light Green Shading, bridge to maintenance therapy; Star, bridge to HSCT; Triangle, discontinuation of blinatumomab due to toxicity; Square, death.